KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Revenue (2016 - 2025)

Rigel Pharmaceuticals has reported Revenue over the past 15 years, most recently at $69.8 million for Q4 2025.

  • For Q4 2025, Revenue rose 21.19% year-over-year to $69.8 million; the TTM value through Dec 2025 reached $294.3 million, up 64.15%, while the annual FY2025 figure was $294.3 million, 64.15% up from the prior year.
  • Revenue for Q4 2025 was $69.8 million at Rigel Pharmaceuticals, roughly flat from $69.5 million in the prior quarter.
  • Over five years, Revenue peaked at $101.7 million in Q2 2025 and troughed at $16.7 million in Q1 2022.
  • A 5-year average of $43.0 million and a median of $32.8 million in 2022 define the central range for Revenue.
  • Biggest five-year swings in Revenue: crashed 79.34% in 2022 and later surged 176.01% in 2025.
  • Year by year, Revenue stood at $20.4 million in 2021, then soared by 151.25% to $51.3 million in 2022, then tumbled by 30.2% to $35.8 million in 2023, then soared by 60.92% to $57.6 million in 2024, then grew by 21.19% to $69.8 million in 2025.
  • Business Quant data shows Revenue for RIGL at $69.8 million in Q4 2025, $69.5 million in Q3 2025, and $101.7 million in Q2 2025.